Soares Karen sold $69K of CLOV

Soares Karen (Chief Legal Officer) sold 14,673 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.68 on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Oct 19, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The disclosed sale adds a modest bearish pressure on CLOV.

02

Market read

A new insider sale of modest size may cause short‑term price pressure.

03

What to watch

The insider retains a large stake of over 1.5 million shares, indicating continued confidence.

Relevance 2/10Novelty 2/10Timing: post-market today

Background

SEC Form 4 filing by Clover Health's Chief Legal Officer.

Company-level read

Ticker impact

$CLOVBearishHigh confidence
Context

Form 4 disclosed Chief Legal Officer sold 14,673 shares for $68,670, a new insider sale.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A C-level insider sold a sizable block, which typically weighs on the stock in the short term.

Market effects

Minimal impact on the health‑tech sector.

Limited to U.S. markets where CLOV trades.

Low

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Soares Karen

    Chief Legal Officer of Clover Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.